Navigating the GLP-1 Landscape: Clinical, Commercial, and Care Considerations

The rapid expansion of GLP-1 receptor agonists has created unprecedented opportunities and challenges across the healthcare ecosystem, transforming treatment paradigms for diabetes, obesity, and potentially other conditions. This therapeutic revolution extends beyond clinical efficacy to encompass complex considerations around access, affordability, care delivery models, and long-term health system impacts that require coordinated responses from multiple stakeholders.

This discussion will explore how healthcare organizations, payers, and pharmaceutical companies are navigating the multifaceted implications of GLP-1 adoption, from optimizing clinical outcomes and managing supply constraints to developing sustainable coverage models and addressing care equity concerns. We'll examine emerging best practices for GLP-1 implementation while addressing the broader strategic questions these medications raise for healthcare delivery and population health management.

Join us to discuss:

• How are healthcare organizations developing comprehensive approaches to GLP-1 prescribing, monitoring, and patient support that optimize clinical outcomes while managing resource constraints?
• What strategies are payers and health systems implementing to balance GLP-1 access with cost management and long-term sustainability considerations?
• How might the GLP-1 revolution reshape obesity and diabetes care delivery models, patient expectations, and population health strategies?